Close Menu

NEW YORK (GenomeWeb) – Researchers plan to develop a gut microbiome signature of nonalcoholic fatty liver disease-linked cirrhosis into a diagnostic test for the condition.

Between 20 percent and 30 percent of US adults have nonalcoholic fatty liver disease (NAFLD), a condition in which excess fat is stored in the liver, according to the National Institute of Diabetes and Digestive and Kidney Diseases. It's more common among people with obesity and type 2 diabetes and can lead to cirrhosis, which is itself a risk factor for liver cancer.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

This webinar will discuss a next-generation sequencing approach for detecting genomic mutations in hematologic maglignancies.


This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.


This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.